BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 275.49B +6.5% |
| Revenue (ttm) | 45.00B +37.4% |
| Net Income | 4.02B |
| EPS | 34.53 |
| Shares Out | n/a |
| PE Ratio | 68.49 |
| Forward PE | 45.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,125,482 |
| Open | 196.00 |
| Previous Close | 196.10 |
| Day's Range | 192.90 - 197.00 |
| 52-Week Range | 153.00 - 229.40 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 256.62 (+32.28%) |
| Earnings Date | Aug 5, 2026 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Analyst Summary
According to 16 analysts, the average rating for 6160 stock is "Strong Buy." The 12-month stock price target is $256.62, which is an increase of 32.28% from the latest price.
News
BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment
(RTTNews) - BeOne Medicines Ltd. (ONC) announced a $300 million expansion of its flagship manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing its tot...
BeOne Medicines price target raised to $425 from $415 at JPMorgan
JPMorgan raised the firm’s price target on BeOne Medicines (ONC) to $425 from $415 and keeps an Overweight rating on the shares. The firm believes BeOne has the “clearest fundamental…
BeOne announces $300 million expansion of US manufacturing facility
BeOne Medicines announced on Thursday an additional $300 million investment to a manufacturing and R&D facility in New Jersey, bringing total U.S. manufacturing investment to more than $1 billion, it ...
BeOne Medicines to invest $300M in New Jersey R&D center
BeOne Medicines (ONC) announced a $300M expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, N...
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. announced a $300 million expansion of its manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, N...
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on W...
BeOne Medicines price target lowered to $403 from $409 at Barclays
Barclays lowered the firm’s price target on BeOne Medicines (ONC) to $403 from $409 and keeps an Overweight rating on the shares. The firm adjusted the price target as part…
BeOne Medicines upgraded to Buy from Hold at Jefferies
Jefferies upgraded BeOne Medicines (ONC) to Buy from Hold with a price target of $380, up from $333. The firm sees the company’s Brukinsa maintaining its dominance and believes ZS…
BeOne Medicines (ONC) Receives FDA Orphan Designation for Pancreatic Cancer Treatment
BeOne Medicines (ONC) Receives FDA Orphan Designation for Pancreatic Cancer Treatment
BeOne Medicines treatment of pancreatic cancer granted orphan status
BeOne Medicines (ONC)’ MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency’s website.
BeOne Medicines price target raised to $416 from $413 at Truist
Truist raised the firm’s price target on BeOne Medicines (ONC) to $416 from $413 and keeps a Buy rating on the shares as part of a broader research note previewing…
BeOne Medicines price target raised to $451 from $436 at RBC Capital
RBC Capital raised the firm’s price target on BeOne Medicines (ONC) to $451 from $436 and keeps an Outperform rating on the shares as part of a broader research note…
BeOne Medicines (ONC) Reports Positive Phase 3 MANGROVE Study Results
BeOne Medicines (ONC) Reports Positive Phase 3 MANGROVE Study Results
BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
BeOne Medicines (ONC) announced positive topline results from the Phase 3 MANGROVE study evaluating foundational BTK inhibitor Brukinsa – zanubrutinib – plus rituximab versus bendamustine plus rituxim...
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 ...
BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology ...
BeOne Medicines announces presentation of Phase 3 data in CLL patients
BeOne Medicines (ONC) announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL, aged 80 and older, showing sustained b...
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 datase...
BeOne Medicines AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Five solid tumor programs are prioritized for phase III, with rapid global development and robust go/no-go criteria. Financial guidance was raised following strong Q1 results, and BRUKINSA leads the BTK inhibitor market. New launches and pipeline assets show strong efficacy and safety, with innovation in bispecifics and trispecifics.
BeOne Medicines price target raised to $436 from $425 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on BeOne Medicines (ONC) to $436 from $425 and keeps an Outperform rating on the shares. At ASCO, the company…
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company sai...
BeOne Medicines AG Transcript: Study update
Three solid tumor programs—CDK4 inhibitor in breast cancer, B7-H4 ADC in ovarian cancer, and GPC3x4-1BB bispecific in HCC—show strong efficacy and favorable safety, with all on track for registrational studies. The pipeline leverages rapid development and broad combinability.
BeOne Medicines AG Press release: Study update
BeOne Medicines AG issued a press release on June 1, 2026, disclosing material business information to investors.
BeOne Medicines AG Slides: Study update
BeOne Medicines AG has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...